Morbus Parkinson

Feverstein TJ (2005) Antiparkinsonmittel. Pharmakother-apie des Morbus Parkinson. In Aktories K, Forstermann U, Hofmann F, and Starke K (eds) Allgemeine und spezielle Pharmakologie und Toxikologie, 9. Auflage, Urban Fischer, Miinchen Jena, pp 305-311... 

Safinamide is a mixed Na+ and Ca2+ channel blocker with anticonvulsant, neuroprotective and anti-parkinsonian properties and is currently in phase II clincical trials for the indications epilepsy and Morbus parkinson (for review see Chazot, 2001). Additionally, analgesic activity has been shown in acute pain models (hot plate, tail flick) and more pronounced in a chronic, persistent pain model (formalin test) in mice in a dose range of 7.5 to 120 mg/kg p.o. (Salvati et al., 1999). 

Using the described process, roughly 1 ton per year of L-dopa was produced between 1985 and 1990. The first tablets were put on sale under the name of Isicom (Fig. 14) in January 1986 and were a combination of L-dopa and L-carbidopa [L-car-bidopa = (S)-2-hydrazino-2-(3,4-dihydroxybenzyl)-propionic acid monohydrate] also prepared in Zwickau by a new process developed by Schmitz and Andreae [36, 37]. The presence of small amounts of carbidopa is very important, allowing a considerable minimization of the amount of L-dopa required for the effective treatment of the symptoms of the Morbus Parkinson. 

Madeja, U.D. (1992) Der Dopamin-Agonist Lisurid in der Therapie des Morbus Parkinson. Acta Histochem. 8 (Suppl. XLII) 25-31. 

---